Delcath Systems, Inc.

NASDAQ:DCTH

Medical - Devices

Healthcare
$19.70 -1.91%

-$0.23 today

Market cap
$685.32M
Beta
0.52
P/E (TTM)
751.4
EPS (TTM)
$0.02
52W Low $8.12High $14.48

Volume 0.59M

Average 0.42M

DCTH Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Delcath Systems, Inc.NASDAQ: DCTH

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $2.42M (cash outflow) fell 20.9% year over year, ahead of the -98.2% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +38.4% a year.

Context

  • Accounts receivables amounted to 1.0% of revenue in FY2025, down 27.6 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -20.9% holds above the trailing-twelve-month pace of -98.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.42M-220.3% QoQ
Last fiscal yearDec 2025
-$854K-92.0% YoY
LTMMar 2026
-$217K-98.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.9%——
1 year-92.0%——
3-year CAGR+38.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(854K) USD
Year-over-year change
+92.0%

Accounts Receivables vs competitors

How DCTH compares with its peers on the latest reported figures

  • DCTH's LTM Mar 2026 accounts receivables of $217K is the 3rd largest of the 4 companies compared; the peer median is $440K.
  • Its year-over-year change of -98.2% is the 3rd highest of 4, against a peer median of -6.9%.
  • Accounts receivables amounts to 0.2% of revenue for DCTH, versus a peer median of 4.4%.
DCTH Competitors Peer median
Accounts Receivables for DCTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$29.5M -6.9%—4.4%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$440K -119.2%—71.2%
DCTHDelcath Systems, Inc.LTM Mar 2026$217K -98.2%+38.4%0.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$23K +101.7%+101.4%0.1%
Peer median (excluding DCTH) $440K-6.9%+101.4%4.4%

Competitors are the stored peer set for DCTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.65M)(36.51M)(47.68M)(26.39M)2.7M
Depreciation & Amortization146K132K128K229K349K
Deferred Income Tax00000
Stock-Based Compensation7.83M7.94M8.15M9.77M24.23M
Change in Working Capital(5.76M)2.11M(906K)(15.52M)(3.07M)
Accounts Receivables13K(322K)125K(10.65M)(854K)
Inventory(557K)(587K)(1.32M)(3.61M)(3.32M)
Accounts Payables(1.14M)1.8M(199K)479K4.77M
Other Working Capital(4.08M)1.23M492K(1.74M)(3.66M)
Other Non-Cash Items831K1.37M9.05M13.23M(1.7M)
Operating Cash Flow(22.6M)(24.95M)(31.25M)(18.68M)22.52M
Capital Expenditures(143K)(209K)(58K)(559K)(1.55M)
Acquisitions (Net)00000
Purchases of Investments00(19.65M)(52.45M)(93.22M)
Sales of Investments00052.03M68.17M
Other Investing Activities00000
Investing Cash Flow(143K)(209K)(19.71M)(981K)(26.59M)
Debt Repayment14.44M(714K)(6.31M)(10.61M)0
Common Stock Issued3.92M10.86M23.08M7.02M21.05M
Common Stock Repurchased0000(6M)
Dividends Paid00000
Other Financing Activities2.46M035.01M43M0
Financing Cash Flow20.82M10.14M51.78M39.41M15.05M
Effect of Forex Changes122K(115K)56K(32K)68K
Net Change in Cash(1.8M)(15.13M)874K19.72M11.04M
Free Cash Flow(22.75M)(25.16M)(31.31M)(19.24M)20.97M

Delcath Systems, Inc.

NASDAQ:DCTH

Intrinsic Alpha fair value

Locked

Current Price

$19.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.